Novinject

Problem to solve: - Manufacturing microneedle solutions to deliver liquid solutions into the skin requires complicated technologies and high production costs. We have developed and patented a solution to produce hollow polymer microneedle arrays using a highly industrializable method (injection molding). - A one fit all solution is not possible because depending on the solution to inject, the injection device caracteristics should be optimized. Solution found: Our value proposition is:"We are the first choice partner for biopharma and biotech companies looking for highly customized microneedles. Unlike competitors, Novinject offers high customization at lower cost” Business Model: - Our key activities are sales and marketing, product development and master production. - Novinject is a lean structure with a CTO, a CFO and a CEO to start. - Our key partners are ou subcontractors (manufacturing), and regulatory affairs advisors. - Our clients are biopharma, biotech or other companies. - Our revenues come from developments contracts that we sell to clients and royalties on each product they sell. The Novinject team is composed of 3 persons with complementary skills and exertise. We are entrepreneurial minds, driven by passion and new challenges Target Market / Size: In 2012, the global market for drug administration technologies using injections represented 22,5 billions dollars. This market is expected to have an annual growth of 14% to reach 43,3 billions dollars in 2017. The market for new means of drug administration thus grows 3 times faster than the pharmaceutical market. "Sources : IMS health and mddionline" Customers - Current / Potential: - Biosensors companies - Dermo-cosmetic companies - Bio-pharma companies - Bio-similars companies Sales / Marketing Strategy: There is a gap between pharma expectations and technology readiness. To attract big/middle size pharma, Novinject needs to develop a wide range of solutions. Unlike our competitors we propose customized products